<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02359877</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-054-1</org_study_id>
    <nct_id>NCT02359877</nct_id>
  </id_info>
  <brief_title>Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international multicenter study of tolerability, pharmacokinetics and
      pharmacodynamics of drug product BCD-054 (CJSC BIOCAD, Russia), administrated intramuscular
      and subcutaneous, compared to Rebif® (Merck Serono S.p.A., Italy) and Avonex® (Biogen Idec
      Ltd, UK) in healthy volunteers. The study involves 2 stages - single ascending dose
      administration and multiple estimated therapeutic dose administration of BCD-054.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (0-168); AUC (0-336); AUC (0-672); AUC (0-∞ ) of Interferon (IFN) Beta-1a</measure>
    <time_frame>0 to 168 hours; 0 to 336 hours; 0 to 672 hours respectively</time_frame>
    <description>Stage 1 primary outcome measure for pharmacokinetics analysis. Area under concentration-time curve (AUC) of interferon (IFN) beta-1a from the moment of drug administration up to 168, 336, 648 hours respectively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-last); AUC (0-∞ ) BCD-054 of Interferon (IFN) Beta-1a - 180 mcg - SC, BCD-054 - 180 mcg - IM</measure>
    <time_frame>0 to 672 hours</time_frame>
    <description>Stage 2 primary outcome measure for pharmacokinetics analysis. Area under concentration-time curve (AUC) of interferon (IFN) beta-1a from the moment of drug administration until last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-168); AUC (0-336); AUC (0-672);AUC (0-∞ ) of Neopterin</measure>
    <time_frame>0 to 168 hours; 0 to 336 hours; 0 to 672 hours respectively</time_frame>
    <description>Stage 1 primary outcome measure for pharmacodynamics analysis. Area under concentration-time curve (AUC) of neopterin from the moment of drug administration until 168, 336, 648 hours respectively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-∞), AUC(0-last) of Neopterin</measure>
    <time_frame>0 to 672 hours</time_frame>
    <description>Stage 2 primary outcome measure for pharmacodynamics analysis. Area under concentration-time curve (AUC) of neopterin from the moment of drug administration until last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event (AE) and Serious Adverse Event (SAE) Incidence</measure>
    <time_frame>4 weeks</time_frame>
    <description>Stage 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event (AE) and Serious Adverse Event (SAE) Incidence BCD-054 - 180 mcg - SC/IM</measure>
    <time_frame>4 weeks</time_frame>
    <description>Stage 2 BCD-054 - 180 mcg - SC/IM</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BCD-054</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated interferon beta 1a Single doses - 60 mcg, SC/IM Single doses - 120 mcg, SC/IM Single doses - 240 mcg, SC/IM Single doses - 360 mcg, SC/IM Multiple doses - 180 mcg, SC/IM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rebif</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>interferon beta 1a 44 mcg, SC, 3 times a week for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avonex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>interferon beta 1a 30 mcg, IM, once a week for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCD-054</intervention_name>
    <arm_group_label>BCD-054</arm_group_label>
    <other_name>pegylated interferon beta 1a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebif</intervention_name>
    <arm_group_label>Rebif</arm_group_label>
    <other_name>interferon beta 1a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avonex</intervention_name>
    <arm_group_label>Avonex</arm_group_label>
    <other_name>interferon beta 1a</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        InInclusion Criteria:

          1. Written informed consent;

          2. Male gender;

          3. Age 18 - 45 years inclusive;

          4. Body mass index (BMI) (18,5 - 24,99 kg/m2);

          5. Healthy condition proven by the volunteer's history, global assessment and laboratory
             analysis results:

               -  Absence in past medical history and at screening of clinically significant
                  dysfunctions of circulatory, respiratory, nervous, hematopoietic, endocrine and
                  digestive systems, liver and kidneys;

               -  No history of cardiovascular diseases and diseases of the thyroid gland

               -  Haematology and biochemistry tests, urinalysis and thyroid hormone analysis
                  results are within normal limits according to standards of the study site.
                  Screening laboratory analyses should be performed not more than 14 days before
                  volunteer's inclusion in the study;

               -  Hemodynamic parameters are within normal limits: systolic blood pressure - from
                  100 to 139 mmHg, diastolic blood pressure - from 60 to 90 mmHg, heart rate - from
                  50 to 90 bpm;

               -  Absence of history of chronic infection (tuberculosis) and chronic inflammation;

               -  Absence of HIV, hepatitis B and C virus, syphilis;

               -  Absence of acute infections within 4 weeks before inclusion in the study;

               -  Absence of psychiatric disorders and other conditions that can interfere with
                  volunteer's ability to follow the study protocol, including depression;

               -  Well-being (in volunteer's opinion) within 30 days before participation in the
                  study;

          6. Absence of history of systematic alcohol and drug abuse;

          7. Ability of the volunteer, in investigator's opinion, to follow the study protocol
             procedures and requirements;

          8. Willingness of volunteers and their sexual partners of childbearing potential to use
             reliable contraception methods starting from 2 weeks before inclusion into the study
             and until 4 weeks after receiving the last dose of the investigational products. This
             criterion is not applicable to patients who underwent surgical sterilization. Reliable
             contraceptive measures include one barrier method in combination with one of the
             following methods: spermicides, intrauterine device or oral contraceptives used by
             participant's partner;

          9. Consent to avoid alcohol intake within 24 hours before and 8 days after each
             administration of the test or reference drugs;

         10. Consent to avoid grapefruit juice (or other products containing grapefruit) intake
             within 72 hours before and 8 days after each administration of the study or reference
             drugs.

        Exclusion Criteria:

          1. Previous use of IFN-β1-containing medications at any time before inclusion;

          2. History of serious allergic reactions (anaphylaxis or multiple allergy);

          3. Known allergy or intolerance to interferons or any other components of study or
             reference drugs or pegylated proteins;

          4. Major surgery within 30 days before screening;

          5. Impossibility to install venous catheter for blood sampling (e.g. because of skin
             disorders at the sites of venipuncture);

          6. Diseases or other conditions that can interfere with the investigational drugs
             pharmacokinetics (e.g. chronic liver, kidney, blood, circulatory system, lung or
             neuroendocrine diseases, including diabetes mellitus and others);

          7. History of fever over 40°С

          8. History of increase in aminotransferases (ALT, AST) &gt; 2.5 × ULN

          9. History of epileptic seizures;

         10. Depression and/or suicidal ideas, suicide attempts in history

         11. Regular oral or parenteral use of any medications including over-the-counter drugs,
             vitamins and nutritional additives within less than 2 weeks before inclusion in the
             study;

         12. Intake of medications, including over-the-counter drugs and biologically active
             additives that can influence hemodynamics, liver function etc. (barbiturates,
             omeprazole, cimetidine etc.) within less than 30 days before inclusion in the study;

         13. Intake of medications that influence immune status (cytokines and their inductors,
             glucocorticoids etc.) within less than 30 days before inclusion in the study;

         14. Vaccination within 4 weeks prior to inclusion

         15. Smoking more than 10 cigarettes per day;

         16. Subjects who consume more than 10 units of alcohol per week or who have history of
             alcohol abuse or evidence of drug/chemical abuse (one unit of alcohol equals ½ l [500
             ml] of beer, one glass [200 ml] of wine or l shot glass [50 ml] of spirits);

         17. Donation of 450 ml and more of blood or plasma within 2 months before inclusion in the
             study;

         18. Participation in other clinical studies within less than 1 month before inclusion in
             the study or simultaneous participation in another clinical study;

         19. Previous participation in this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan Sardaryan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OOO BioEk</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OOO &quot;BioEk&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197342</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.biocad.ru</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2015</study_first_posted>
  <results_first_submitted>March 31, 2016</results_first_submitted>
  <results_first_submitted_qc>October 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2016</results_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pegylated interferon beta</keyword>
  <keyword>Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BCD-054 (Single Doses)</title>
          <description>Pegylated interferon beta 1a (BCD-054) Single doses - 60 mcg, IM/SC; or 120 mcg, IM/SC; or 240 mcg, IM/SC; or 360 mcg, IM/SC</description>
        </group>
        <group group_id="P2">
          <title>Rebif</title>
          <description>interferon beta 1a (Rebif) 44 mcg, SC, 3 times a week for 2 weeks</description>
        </group>
        <group group_id="P3">
          <title>Avonex</title>
          <description>interferon beta 1a (Avonex) 30 mcg, IM, once a week for 2 weeks</description>
        </group>
        <group group_id="P4">
          <title>BCD-054 (Multiple Dose)</title>
          <description>Pegylated interferon beta 1a (BCD-054) Multiple dose - 180 mcg, IM/SC, biweekly, 3 injections</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Presented baseline measures relate to all volunteers who participated in Stage 1.</population>
      <group_list>
        <group group_id="B1">
          <title>BCD-054 (Single Doses)</title>
          <description>Pegylated interferon beta 1a (BCD-054) Single doses - 60 mcg, IM/SC; or 120 mcg, IM/SC; or 240 mcg, IM/SC; or 360 mcg, IM/SC</description>
        </group>
        <group group_id="B2">
          <title>Rebif</title>
          <description>interferon beta 1a (Rebif) 44 mcg, SC, 3 times a week for 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Avonex</title>
          <description>interferon beta 1a (Avonex) 30 mcg, IM, once a week for 2 weeks</description>
        </group>
        <group group_id="B4">
          <title>BCD-054 (Multiple Doses)</title>
          <description>Pegylated interferon beta 1a (BCD-054) Multiple dose - 180 mcg, IM/SC, biweekly, 3 injections</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" lower_limit="21" upper_limit="26"/>
                    <measurement group_id="B2" value="23" lower_limit="21" upper_limit="26"/>
                    <measurement group_id="B3" value="23" lower_limit="21" upper_limit="26"/>
                    <measurement group_id="B4" value="21" lower_limit="20" upper_limit="31"/>
                    <measurement group_id="B5" value="23" lower_limit="21" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-168); AUC (0-336); AUC (0-672); AUC (0-∞ ) of Interferon (IFN) Beta-1a</title>
        <description>Stage 1 primary outcome measure for pharmacokinetics analysis. Area under concentration-time curve (AUC) of interferon (IFN) beta-1a from the moment of drug administration up to 168, 336, 648 hours respectively</description>
        <time_frame>0 to 168 hours; 0 to 336 hours; 0 to 672 hours respectively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-054 - 60 mcg - SC</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 60 mcg, subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>BCD-054 - 60 mcg - IM</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 60 mcg, intramuscular injection</description>
          </group>
          <group group_id="O3">
            <title>BCD-054 - 120 mcg - SC</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 120 mcg, subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>BCD-054 - 120 mcg - IM</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 120 mcg, intramuscular injection</description>
          </group>
          <group group_id="O5">
            <title>BCD-054 - 240 mcg - SC</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 240 mcg, subcutaneously</description>
          </group>
          <group group_id="O6">
            <title>BCD-054 - 240 mcg - IM</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 240 mcg, intramuscular injection</description>
          </group>
          <group group_id="O7">
            <title>BCD-054 - 360 mcg - SC</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 360 mcg, subcutaneously</description>
          </group>
          <group group_id="O8">
            <title>BCD-054 - 360 mcg - IM</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 360 mcg, intramuscular injection</description>
          </group>
          <group group_id="O9">
            <title>Rebif</title>
            <description>interferon beta 1a (Rebif) 44 mcg, SC, 3 times a week for 2 weeks</description>
          </group>
          <group group_id="O10">
            <title>Avonex</title>
            <description>interferon beta 1a (Avonex) 30 mcg, IM, once a week for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-168); AUC (0-336); AUC (0-672); AUC (0-∞ ) of Interferon (IFN) Beta-1a</title>
          <description>Stage 1 primary outcome measure for pharmacokinetics analysis. Area under concentration-time curve (AUC) of interferon (IFN) beta-1a from the moment of drug administration up to 168, 336, 648 hours respectively</description>
          <units>(pg/ml)*hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36682" lower_limit="20348" upper_limit="132888"/>
                    <measurement group_id="O2" value="87085" lower_limit="53718" upper_limit="133586"/>
                    <measurement group_id="O3" value="279477" lower_limit="237578" upper_limit="309910"/>
                    <measurement group_id="O4" value="176866" lower_limit="119715" upper_limit="191402"/>
                    <measurement group_id="O5" value="405395" lower_limit="130963" upper_limit="835348"/>
                    <measurement group_id="O6" value="420038" lower_limit="265413" upper_limit="692759"/>
                    <measurement group_id="O7" value="1052951" lower_limit="534763" upper_limit="1195047"/>
                    <measurement group_id="O8" value="376277" lower_limit="227428" upper_limit="522273"/>
                    <measurement group_id="O9" value="20423" lower_limit="18115" upper_limit="22919"/>
                    <measurement group_id="O10" value="5995" lower_limit="5139" upper_limit="7093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44569" lower_limit="24305" upper_limit="175568"/>
                    <measurement group_id="O2" value="103624" lower_limit="53718" upper_limit="162221"/>
                    <measurement group_id="O3" value="345510" lower_limit="309323" upper_limit="439732"/>
                    <measurement group_id="O4" value="196189" lower_limit="136976" upper_limit="215301"/>
                    <measurement group_id="O5" value="426025" lower_limit="149813" upper_limit="931966"/>
                    <measurement group_id="O6" value="437275" lower_limit="288706" upper_limit="737144"/>
                    <measurement group_id="O7" value="1457973" lower_limit="554150" upper_limit="1625676"/>
                    <measurement group_id="O8" value="407273" lower_limit="243598" upper_limit="564684"/>
                    <measurement group_id="O9" value="36866" lower_limit="33072" upper_limit="51379"/>
                    <measurement group_id="O10" value="6964" lower_limit="6006" upper_limit="8067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44569" lower_limit="24305" upper_limit="185094"/>
                    <measurement group_id="O2" value="107471" lower_limit="53718" upper_limit="175510"/>
                    <measurement group_id="O3" value="351768" lower_limit="329256" upper_limit="457232"/>
                    <measurement group_id="O4" value="196189" lower_limit="136976" upper_limit="215301"/>
                    <measurement group_id="O5" value="426025" lower_limit="149813" upper_limit="938358"/>
                    <measurement group_id="O6" value="437275" lower_limit="288706" upper_limit="737144"/>
                    <measurement group_id="O7" value="1554173" lower_limit="563062" upper_limit="1849940"/>
                    <measurement group_id="O8" value="410751" lower_limit="247529" upper_limit="569632"/>
                    <measurement group_id="O9" value="53715" lower_limit="42627" upper_limit="78467"/>
                    <measurement group_id="O10" value="7544" lower_limit="6645" upper_limit="8596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-∞ )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44569" lower_limit="24305" upper_limit="185094"/>
                    <measurement group_id="O2" value="107471" lower_limit="53718" upper_limit="175510"/>
                    <measurement group_id="O3" value="351768" lower_limit="329256" upper_limit="457232"/>
                    <measurement group_id="O4" value="196189" lower_limit="136976" upper_limit="215301"/>
                    <measurement group_id="O5" value="426025" lower_limit="149813" upper_limit="938358"/>
                    <measurement group_id="O6" value="437275" lower_limit="288706" upper_limit="737144"/>
                    <measurement group_id="O7" value="1562327" lower_limit="563063" upper_limit="1872683"/>
                    <measurement group_id="O8" value="410751" lower_limit="247529" upper_limit="569632"/>
                    <measurement group_id="O9" value="54774" lower_limit="43128" upper_limit="78872"/>
                    <measurement group_id="O10" value="7544" lower_limit="6645" upper_limit="8707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-last); AUC (0-∞ ) BCD-054 of Interferon (IFN) Beta-1a - 180 mcg - SC, BCD-054 - 180 mcg - IM</title>
        <description>Stage 2 primary outcome measure for pharmacokinetics analysis. Area under concentration-time curve (AUC) of interferon (IFN) beta-1a from the moment of drug administration until last quantifiable concentration</description>
        <time_frame>0 to 672 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-054 - 180 mcg - SC</title>
            <description>Pegylated interferon beta 1a (BCD-054)</description>
          </group>
          <group group_id="O2">
            <title>BCD-054 - 180 mcg - IM</title>
            <description>Pegylated interferon beta 1a (BCD-054)</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-last); AUC (0-∞ ) BCD-054 of Interferon (IFN) Beta-1a - 180 mcg - SC, BCD-054 - 180 mcg - IM</title>
          <description>Stage 2 primary outcome measure for pharmacokinetics analysis. Area under concentration-time curve (AUC) of interferon (IFN) beta-1a from the moment of drug administration until last quantifiable concentration</description>
          <units>(pg/ml)*hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-last)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274888" lower_limit="228924" upper_limit="450286"/>
                    <measurement group_id="O2" value="210626" lower_limit="152236" upper_limit="383557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-∞)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316204" lower_limit="245890" upper_limit="484802"/>
                    <measurement group_id="O2" value="218817" lower_limit="152236" upper_limit="383557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-168); AUC (0-336); AUC (0-672);AUC (0-∞ ) of Neopterin</title>
        <description>Stage 1 primary outcome measure for pharmacodynamics analysis. Area under concentration-time curve (AUC) of neopterin from the moment of drug administration until 168, 336, 648 hours respectively</description>
        <time_frame>0 to 168 hours; 0 to 336 hours; 0 to 672 hours respectively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-054 - 60 mcg - SC</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 60 mcg, subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>BCD-054 - 60 mcg - IM</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 60 mcg, intramuscular injection</description>
          </group>
          <group group_id="O3">
            <title>BCD-054 - 120 mcg - SC</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 120 mcg, subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>BCD-054 - 120 mcg - IM</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 120 mcg, intramuscular injection</description>
          </group>
          <group group_id="O5">
            <title>BCD-054 - 240 mcg - SC</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 240 mcg, subcutaneously</description>
          </group>
          <group group_id="O6">
            <title>BCD-054 - 240 mcg - IM</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 240 mcg, intramuscular injection</description>
          </group>
          <group group_id="O7">
            <title>BCD-054 - 360 mcg - SC</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 360 mcg, subcutaneously</description>
          </group>
          <group group_id="O8">
            <title>BCD-054 - 360 mcg - IM</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 360 mcg, intramuscular injection</description>
          </group>
          <group group_id="O9">
            <title>Rebif</title>
            <description>interferon beta 1a (Rebif) 44 mcg, SC, 3 times a week for 2 weeks</description>
          </group>
          <group group_id="O10">
            <title>Avonex</title>
            <description>interferon beta 1a (Avonex) 30 mcg, IM, once a week for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-168); AUC (0-336); AUC (0-672);AUC (0-∞ ) of Neopterin</title>
          <description>Stage 1 primary outcome measure for pharmacodynamics analysis. Area under concentration-time curve (AUC) of neopterin from the moment of drug administration until 168, 336, 648 hours respectively</description>
          <units>nmol/L*hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36681" lower_limit="20348" upper_limit="132887"/>
                    <measurement group_id="O2" value="87084" lower_limit="53717" upper_limit="133585"/>
                    <measurement group_id="O3" value="279477" lower_limit="237578" upper_limit="309909"/>
                    <measurement group_id="O4" value="176865" lower_limit="119715" upper_limit="191401"/>
                    <measurement group_id="O5" value="405394" lower_limit="130963" upper_limit="835348"/>
                    <measurement group_id="O6" value="420038" lower_limit="265413" upper_limit="692758"/>
                    <measurement group_id="O7" value="1052951" lower_limit="534763" upper_limit="1195047"/>
                    <measurement group_id="O8" value="376277" lower_limit="227427" upper_limit="522273"/>
                    <measurement group_id="O9" value="20423" lower_limit="18115" upper_limit="22918"/>
                    <measurement group_id="O10" value="5995" lower_limit="5138" upper_limit="7092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44569" lower_limit="24304" upper_limit="175568"/>
                    <measurement group_id="O2" value="103624" lower_limit="53717" upper_limit="162221"/>
                    <measurement group_id="O3" value="345509" lower_limit="309322" upper_limit="439731"/>
                    <measurement group_id="O4" value="196189" lower_limit="136976" upper_limit="215301"/>
                    <measurement group_id="O5" value="426024" lower_limit="149812" upper_limit="931965"/>
                    <measurement group_id="O6" value="437275" lower_limit="288706" upper_limit="737144"/>
                    <measurement group_id="O7" value="1457972" lower_limit="554150" upper_limit="1625676"/>
                    <measurement group_id="O8" value="407273" lower_limit="243597" upper_limit="564684"/>
                    <measurement group_id="O9" value="36865" lower_limit="33071" upper_limit="51379"/>
                    <measurement group_id="O10" value="6964" lower_limit="6006" upper_limit="8067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44569" lower_limit="24304" upper_limit="185093"/>
                    <measurement group_id="O2" value="107471" lower_limit="53717" upper_limit="175510"/>
                    <measurement group_id="O3" value="351767" lower_limit="329256" upper_limit="457231"/>
                    <measurement group_id="O4" value="196189" lower_limit="136976" upper_limit="215301"/>
                    <measurement group_id="O5" value="426024" lower_limit="149812" upper_limit="938358"/>
                    <measurement group_id="O6" value="437275" lower_limit="288706" upper_limit="737144"/>
                    <measurement group_id="O7" value="1554173" lower_limit="563062" upper_limit="1849939"/>
                    <measurement group_id="O8" value="410750" lower_limit="247529" upper_limit="569632"/>
                    <measurement group_id="O9" value="53714" lower_limit="42626" upper_limit="78466"/>
                    <measurement group_id="O10" value="7544" lower_limit="6644" upper_limit="8596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-∞ )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44569" lower_limit="24304" upper_limit="185093"/>
                    <measurement group_id="O2" value="107471" lower_limit="53717" upper_limit="175510"/>
                    <measurement group_id="O3" value="351767" lower_limit="329256" upper_limit="457231"/>
                    <measurement group_id="O4" value="196189" lower_limit="136976" upper_limit="215301"/>
                    <measurement group_id="O5" value="426024" lower_limit="149812" upper_limit="938358"/>
                    <measurement group_id="O6" value="437275" lower_limit="288706" upper_limit="737144"/>
                    <measurement group_id="O7" value="1562327" lower_limit="563062" upper_limit="1872682"/>
                    <measurement group_id="O8" value="410750" lower_limit="247529" upper_limit="569632"/>
                    <measurement group_id="O9" value="54774" lower_limit="43127" upper_limit="78871"/>
                    <measurement group_id="O10" value="7544" lower_limit="6644" upper_limit="8707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-∞), AUC(0-last) of Neopterin</title>
        <description>Stage 2 primary outcome measure for pharmacodynamics analysis. Area under concentration-time curve (AUC) of neopterin from the moment of drug administration until last quantifiable concentration</description>
        <time_frame>0 to 672 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-054 - 180 mcg - SC</title>
            <description>Pegylated interferon beta 1a (BCD-054)</description>
          </group>
          <group group_id="O2">
            <title>BCD-054 - 180 mcg - IM</title>
            <description>Pegylated interferon beta 1a (BCD-054)</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-∞), AUC(0-last) of Neopterin</title>
          <description>Stage 2 primary outcome measure for pharmacodynamics analysis. Area under concentration-time curve (AUC) of neopterin from the moment of drug administration until last quantifiable concentration</description>
          <units>(nmol/L)*hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-∞)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3757" lower_limit="3334" upper_limit="4655"/>
                    <measurement group_id="O2" value="3431" lower_limit="2568" upper_limit="3614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-last)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3303" lower_limit="3118" upper_limit="4487"/>
                    <measurement group_id="O2" value="3242" lower_limit="2568" upper_limit="3612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Event (AE) and Serious Adverse Event (SAE) Incidence</title>
        <description>Stage 1</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-054 - 60 mcg - SC</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 60 mcg, subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>BCD-054 - 60 mcg - IM</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 60 mcg, intramuscular injection</description>
          </group>
          <group group_id="O3">
            <title>BCD-054 - 120 mcg - SC</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 120 mcg, subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>BCD-054 - 120 mcg - IM</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 120 mcg, intramuscular injection</description>
          </group>
          <group group_id="O5">
            <title>BCD-054 - 240 mcg - SC</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 240 mcg, subcutaneously</description>
          </group>
          <group group_id="O6">
            <title>BCD-054 - 240 mcg - IM</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 240 mcg, intramuscular injection</description>
          </group>
          <group group_id="O7">
            <title>BCD-054 - 360 mcg - SC</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 360 mcg, subcutaneously</description>
          </group>
          <group group_id="O8">
            <title>BCD-054 - 360 mcg - IM</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 360 mcg, intramuscular injection</description>
          </group>
          <group group_id="O9">
            <title>Rebif</title>
            <description>interferon beta 1a (Rebif) 44 mcg, SC, 3 times a week for 2 weeks</description>
          </group>
          <group group_id="O10">
            <title>Avonex</title>
            <description>interferon beta 1a (Avonex) 30 mcg, IM, once a week for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event (AE) and Serious Adverse Event (SAE) Incidence</title>
          <description>Stage 1</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious) Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (Not Including Serious) Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated erythrocyte sedimentation rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leucopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasmatization of lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vacuolation of cytoplasm of monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu-like syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated gamma glutamil transferrase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperemia of injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Event (AE) and Serious Adverse Event (SAE) Incidence BCD-054 - 180 mcg - SC/IM</title>
        <description>Stage 2 BCD-054 - 180 mcg - SC/IM</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-054 - 180 mcg - SC</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 180 mcg, subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>BCD-054 - 180 mcg - IM</title>
            <description>Pegylated interferon beta 1a (BCD-054) Single dose - 180 mcg, intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event (AE) and Serious Adverse Event (SAE) Incidence BCD-054 - 180 mcg - SC/IM</title>
          <description>Stage 2 BCD-054 - 180 mcg - SC/IM</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (Not Including Serious) Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leucopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu-like syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperemia of injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>29 days after injection</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BCD-054 - 60 mcg - SC</title>
          <description>Pegylated interferon beta 1a (BCD-054) Single dose - 60 mcg, subcutaneously</description>
        </group>
        <group group_id="E2">
          <title>BCD-054 - 60 mcg - IM</title>
          <description>Pegylated interferon beta 1a (BCD-054) Single dose - 60 mcg, intramuscular injection</description>
        </group>
        <group group_id="E3">
          <title>BCD-054 - 120 mcg - SC</title>
          <description>Pegylated interferon beta 1a (BCD-054) Single dose - 120 mcg, subcutaneously</description>
        </group>
        <group group_id="E4">
          <title>BCD-054 - 120 mcg - IM</title>
          <description>Pegylated interferon beta 1a (BCD-054) Single dose - 120 mcg, intramuscular injection</description>
        </group>
        <group group_id="E5">
          <title>BCD-054 - 240 mcg - SC</title>
          <description>Pegylated interferon beta 1a (BCD-054) Single dose - 240 mcg, subcutaneously</description>
        </group>
        <group group_id="E6">
          <title>BCD-054 - 240 mcg - IM</title>
          <description>Pegylated interferon beta 1a (BCD-054) Single dose - 240 mcg, intramuscular injection</description>
        </group>
        <group group_id="E7">
          <title>BCD-054 - 360 mcg - SC</title>
          <description>Pegylated interferon beta 1a (BCD-054) Single dose - 360 mcg, subcutaneously</description>
        </group>
        <group group_id="E8">
          <title>BCD-054 - 360 mcg - IM</title>
          <description>Pegylated interferon beta 1a (BCD-054) Single dose - 360 mcg, intramuscular injection</description>
        </group>
        <group group_id="E9">
          <title>Rebif</title>
          <description>interferon beta 1a (Rebif) 44 mcg, SC, 3 times a week for 2 weeks</description>
        </group>
        <group group_id="E10">
          <title>Avonex</title>
          <description>interferon beta 1a (Avonex) 30 mcg, IM, once a week for 2 weeks</description>
        </group>
        <group group_id="E11">
          <title>BCD-054 - 180 mcg - SC</title>
          <description>Pegylated interferon beta 1a (BCD-054) Single dose - 180 mcg, subcutaneously</description>
        </group>
        <group group_id="E12">
          <title>BCD-054 - 180 mcg - IM</title>
          <description>Pegylated interferon beta 1a (BCD-054) Single dose - 180 mcg, intramuscular injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Monocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vacuolation of cytoplasm of monocytes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Trombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Elevated erythrocyte sedimentation rate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Plasmatization of lymphocytes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Monocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Elevated gamma glutamil transferrase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperemia of injection site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biryulin Andrey</name_or_title>
      <organization>BIOCAD</organization>
      <phone>+7812380 49 33 ext 925</phone>
      <email>biryulin@biocad.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

